Skip to main content
Premium Trial:

Request an Annual Quote

Atugen, Schering Pen Gene-Function Deal

NEW YORK, Sept. 17 - Atugen said today that Schering has chosen it to help perform drug-target and gene-function studies.


The one-year agreement calls for Atugen to develop antisense oligonucleotides that inhibit the expression of certain undisclosed drug targets picked by Schering. The two German companies will then analyze the oligos, called GeneBlocs, in the hopes of validating gene function and disease association, the partners said.


The deal comes on the heals of a five-year drug target-validation collaboration that ends this year between Atugen, Schering, and Schering's US-based research group Berlex Biosciences.

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.